近日，甘李药业与晶泰科技宣布达成战略合作，双方将围绕人工智能驱动的药物研发展开深度合作。甘李药业作为中国领先的胰岛素及糖尿病治疗产品研发企业，致力于为全球患者提供高质量的创新疗法；而晶泰科技则是以AI和量子物理为核心的前沿科技公司，在小分子药物发现、晶型预测及制剂优化等领域拥有领先技术。此次合作将结合甘李药业在生物医药领域的深厚积累与晶泰科技在AI制药方面的强大算力与算法优势，加速新药候选分子的筛选与优化，缩短研发周期，降低开发成本。双方计划首先聚焦于糖尿病及相关代谢疾病的创新药物开发，并探索AI在蛋白质工程、多肽药物设计等方向的应用潜力。这一合作标志着传统制药企业与AI科技公司融合的新范式，有望推动中国乃至全球创新药研发效率的提升，为患者带来更快、更精准的治疗方案。
Recently, Gan & Lee Pharmaceuticals and XtalPi announced a strategic collaboration focused on AI-driven drug discovery. Gan & Lee, a leading Chinese biopharmaceutical company specializing in insulin and diabetes therapeutics, is committed to delivering high-quality innovative treatments globally. XtalPi, a cutting-edge tech firm leveraging artificial intelligence and quantum physics, excels in small-molecule drug discovery, crystal form prediction, and formulation optimization. By combining Gan & Lee’s deep expertise in biopharma with XtalPi’s advanced AI algorithms and computational power, the partnership aims to accelerate the screening and optimization of novel drug candidates, shorten development timelines, and reduce R&D costs. The initial focus will be on innovative therapies for diabetes and related metabolic disorders, with potential exploration into AI applications in protein engineering and peptide drug design. This collaboration represents a new paradigm of integration between traditional pharmaceutical companies and AI-driven tech firms, promising to enhance drug discovery efficiency in China and worldwide, ultimately delivering faster and more precise treatments to patients.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/700.html